67 related articles for article (PubMed ID: 38633126)
1. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Zhao J; Song Y; Liu D
Biomark Res; 2019; 7():19. PubMed ID: 31528345
[TBL] [Abstract][Full Text] [Related]
2. Post-stem cell transplant maintenance in FLT3
Ashouri K; Chennapan K; Martynova A; Nazaretyan S; Ali A; Ginosyan AA; Tam E; Ladha A; Woan K; Chaudhary P; Siddiqi I; Yaghmour G
EJHaem; 2024 Apr; 5(2):423-427. PubMed ID: 38633126
[No Abstract] [Full Text] [Related]
3. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Recher C; Yoon SS; Maeda Y; Hosono N; Onozawa M; Kato T; Kim HJ; Hasabou N; Nuthethi R; Tiu R; Levis MJ
Transplant Cell Ther; 2023 Apr; 29(4):265.e1-265.e10. PubMed ID: 36526260
[TBL] [Abstract][Full Text] [Related]
5. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Numan Y; Abdel Rahman Z; Grenet J; Boisclair S; Bewersdorf JP; Collins C; Barth D; Fraga M; Bixby DL; Zeidan AM; Yilmaz M; Desai P; Mannis G; Deutsch YE; Abaza Y; Dinner S; Frankfurt O; Litzow M; Al-Kali A; Foran JM; Sproat LZ; Jovanovic B; Daver N; Perl AE; Altman JK
Am J Hematol; 2022 Mar; 97(3):322-328. PubMed ID: 34981560
[TBL] [Abstract][Full Text] [Related]
6. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
Daver N; Venugopal S; Ravandi F
Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Perl AE; Hosono N; Montesinos P; Podoltsev N; Martinelli G; Panoskaltsis N; Recher C; Smith CC; Levis MJ; Strickland S; Röllig C; Groß-Langenhoff M; Chou WC; Lee JH; Yokoyama H; Hasabou N; Lu Q; Tiu RV; Altman JK
Blood Cancer J; 2022 May; 12(5):84. PubMed ID: 35637252
[TBL] [Abstract][Full Text] [Related]
8. Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML.
Terao T; Matsuoka KI; Ueda H; Matsumura A; Matsubara C; Kondo K; Kondo T; Fujiwara H; Asada N; Ennishi D; Nishimori H; Fujii K; Fujii N; Maeda Y
Blood Adv; 2023 Mar; 7(5):681-686. PubMed ID: 36583677
[No Abstract] [Full Text] [Related]
9. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.
Biavasco F; Zeiser R
Int J Hematol; 2022 Sep; 116(3):341-350. PubMed ID: 35460465
[TBL] [Abstract][Full Text] [Related]
10. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
Zhang Z; Hasegawa Y; Hashimoto D; Senjo H; Kikuchi R; Chen X; Yoneda K; Sekiguchi T; Kawase T; Tsuzuki H; Ishio T; Ara T; Ohigashi H; Nakagawa M; Teshima T
Bone Marrow Transplant; 2022 May; 57(5):775-780. PubMed ID: 35228711
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Récher C; Yoon SS; Hosono N; Onozawa M; Chiba S; Kim HJ; Hasabou N; Lu Q; Tiu R; Levis MJ
Blood; 2022 Jun; 139(23):3366-3375. PubMed ID: 35081255
[TBL] [Abstract][Full Text] [Related]
12.
Kennedy VE; Smith CC
Front Oncol; 2020; 10():612880. PubMed ID: 33425766
[TBL] [Abstract][Full Text] [Related]
13. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
Maziarz RT; Levis M; Patnaik MM; Scott BL; Mohan SR; Deol A; Rowley SD; Kim DDH; Hernandez D; Rajkhowa T; Haines K; Bonifacio G; Rine P; Purkayastha D; Fernandez HF
Bone Marrow Transplant; 2021 May; 56(5):1180-1189. PubMed ID: 33288862
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]